Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: leibo who wrote (453)	1/8/1997 10:16:00 AM
From: Henry Niman	of 32384

leibo, This morning Dow Jones came out with a synopsis of the two PRNewswire press releases that came out last night.. This morning there has been retail profit taking. I think the day traders are exiting which is providing a dip for the big boys who usually don't buy at the open. Here's the Dow Jones release: Allergan Ligand Says It Reaches 2 Milestones For Panretin Dow Jones News Service ~ January 8, 1997 ~ 8:47 am EST SAN FRANCISCO (Dow Jones)--Allergan Ligand Retinoid Therapeutics Inc. (ALRIZ) said it reached two milestones in its clinical trials of the use of Panretin Topical Gel for Kaposi's sarcoma. The milestones are related to statistically significant activity in a phase I/II study. In a press release, Allergan said results of the trial will be useful in supporting a new drug application based upon an ongoing pivotal phase III trial. It plans to file that application in the 1997 fourth quarter if the phase III trial is succesful. Allergan also said it intends to expand the phase III trial by about 35 patients in order to ensure it achieves the desired statistical power on evaluable patients. Allergan said this should not delay the filing of the new drug application. Kaposi's sarcoma is a skin affliction associated with AIDS. In a separate release, Allergan said it expects to designate two of its three advanced pre-clinical compounds as clinical candidates during 1997. The three compounds being considered are an RXR selective agonist, an RAR alpha agonist and an RAR antagonist. Two of the three are expected to go to human trials in 1998. The compounds have possible applications in the treatment of diabetes and cancer. Allergan develops drugs based on retinoids. It is a joint venture of Ligand Pharmaceuticals Inc. (LGND) and Allergan Inc. (AGN). (END) DOW JONES NEWS 01-08-97 8:47 AM Company Symbols: AGN ALRIZ LGND Subject Codes: I/BTC I/DRG I/MTC N/ARI N/DJN N/DJWI N/HLT N/RND M/NCY M/TEC P/DPH R/CA R/NME R/PRM R/US R/USW

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next